Drug General Information
Drug ID
D06KTY
Former ID
DNC000890
Drug Name
Loxiglumide
Drug Type
Small molecular drug
Indication Discovery agent Investigative [530560], [543284]
Structure
Download
2D MOL

3D MOL

Formula
C21H30Cl2N2O5
InChI
InChI=1S/C21H30Cl2N2O5/c1-3-4-5-11-25(12-6-13-30-2)21(29)18(9-10-19(26)27)24-20(28)15-7-8-16(22)17(23)14-15/h7-8,14,18H,3-6,9-13H2,1-2H3,(H,24,28)(H,26,27)
InChIKey
QNQZBKQEIFTHFZ-UHFFFAOYSA-N
CAS Number
CAS 107097-80-3
PubChem Compound ID
PubChem Substance ID
Target and Pathway
Target(s) CCK receptor Target Info Antagonist [538000]
Cholecystokinin receptor type A Target Info Antagonist [535619]
KEGG Pathway Calcium signaling pathway
Neuroactive ligand-receptor interaction
Insulin secretion
Pancreatic secretion
Reactome Peptide ligand-binding receptors
G alpha (q) signalling events
WikiPathways GPCRs, Class A Rhodopsin-like
Gastrin-CREB signalling pathway via PKC and MAPK
Peptide GPCRs
GPCR ligand binding
GPCR downstream signaling
References
Ref 530560Effects of CCK receptor blockade on intestinal motor activity in conscious dogs. Am J Physiol. 1991 Feb;260(2 Pt 1):G315-24.
Ref 543284(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 892).
Ref 535619Role of CCK(A) receptors in postprandial lower esophageal sphincter function in morbidly obese subjects. Dig Dis Sci. 2002 Nov;47(11):2531-7.
Ref 538000Cholecystokinin receptor antagonist, loxiglumide, inhibits invasiveness of human pancreatic cancer cell lines. FEBS Lett. 1996 Apr 1;383(3):241-4.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.